Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
- Resource Type
- article
- Authors
- Bolívar Luis Díaz‐Jordán; Tamara Cebanu; Sara García Barcenilla; Maria Teresa Álvarez‐Román
- Source
- Clinical Case Reports, Vol 11, Iss 12, Pp n/a-n/a (2023)
- Subject
- hemophilia B
pediatrics
prophylaxis
rIX‐FP
Medicine
Medicine (General)
R5-920
- Language
- English
- ISSN
- 2050-0904
Key Clinical Message Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited mobility and overloaded healthcare services.